Sickle cell therapies: GlycoMimetics and others target underlying causes

The standard of care in sickle cell anemia is treatment of pain during vaso-occlusive crisis (VOC) that occurs when sickled cells adhere and block the flow of blood and oxygen, but there are a handful of therapies in development that seek to transform treatment of the disease by interrupting blockages or preventing sickled cells.